MedTrace Logo

Corneal Epithelial Stem Cells and Dry Eye Disease

NCT03302273 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2022-04-21

No results posted yet for this study

Summary

To study of a novel, therapeutic Human Cells, Tissues, and Cellular and Tissue-Based Product (HCT/P) in the treatment of severe dry eye disease that is failing conventional treatments. This pilot study will carefully observe and monitor each qualifying and willing individual for response to treatment, signs of toxicity and adverse effects from the treatment, and for ability of the treatment to improve comfort and restore vision.

Conditions

  • Dry Eye Syndromes
  • Dry Eye
  • Ocular Inflammation
  • Ocular Surface Disease
  • Ocular Discomfort
  • Blepharitis

Interventions

OTHER

Corneal Epithelial Stem Cell Transplant

Self-administration of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material.

Sponsors & Collaborators

  • Sloan W. Rush, MD

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2022-04-01
Completion
2022-04-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03302273 on ClinicalTrials.gov